biostudies-literatureSpigel DRNCI NIH HHS1301-1311https://www.ebi.ac.uk/biostudies/studies/S-EPMC9015199biostudies-literatureUnknown40(12)<h4>Purpose</h4>The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; <i>P</i> = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; <i>P</i> < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned.<h4>Methods</h4>Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 Journal of clinical oncology : official journal of the American Society of Clinical OncologyFive-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.PMC9015199P30 CA008748Vansteenkiste JFNaidoo JReck MGarassino MCSpigel DRGray JERimner AWu YLVicente DQuantin XCho BCNewton MFaivre-Finn CKurata THui RPaz-Ares LSenan SAntonia SJKato TThiyagarajah Pde Wit MMann HOzguroglu MPlanchard DLee KHfalseFive-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.<h4>Purpose</h4>The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; <i>P</i> = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; <i>P</i> < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned.<h4>Methods</h4>Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 2022-01-01T00:00:00Z2022 Apr2025-04-20T00:18:15.46Z2025-02-19T01:53:29.024ZS-EPMC90151993510805910.1200/JCO.21.01308